T2 breast cancer presenting with diffuse liver metastases and hepatic failure following fertility treatment. Cautionary report  by Sule, Emmanuel A.
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BACKGROUND:  Diffuse  hepatic  metastases  with  hepatic  failure  as  a presentation  of a T2  breast  cancer  is
rare.  This  is also  remarkable  seeing  our case  had  been  on  fertility  treatments  before  presentation.  There
are  no documented  reports  of  breast  cancer  patient  on  fertility  treatment  presenting  with  diffuse  hepatic
metastases  and  liver  failure.
CASE  SUMMARY:  A 41 year  old  Para  1 Nigerian  woman  being  managed  for  secondary  infertility  with  an
extended  use  of  clomiphene  presented  with  a 3 months  history  of a left  breast  lump,  nipple  bleeding
and  later,  yellowness  of eyes,  right  hypochondrial  pain  malaise  and  drowsiness.  Abdominal  USS  showed
an  enlarged  liver  with  diffuse  metastatic  nodules.  Liver  function  tests  showed  persistently  elevatingnfertility
epatic metastases
epatic failure
liver  enzymes  and  serum  bilirubin.  Serology  showed  Hepatitis  B negative.  She  was diagnosed  with  a
T2  left  invasive  ductal  carcinoma,  Er−, Pr+  Her2+  with  deteriorating  liver  function  from  diffuse  hepatic
metastases  She  had  chemotherapy  but succumbed  barely  a week  of  presentation.
CONCLUSION:  Breast  cancer  screening  for patients  before  fertility  treatments  and  continual  surveillance
while  on such  treatment  is highly  recommended.
© 2016  The  Author(s).  Published  by Elsevier  Ltd on behalf  of  IJS Publishing  Group  Ltd.  This  is  an  open
he CCaccess  article  under  t
. Introduction
Although hepatic metastases from breast cancer is not an
ncommon presentation with reported incidence at 40–50% [1]
epatic failure as a presentation of metastatic breast cancer is very
are. Rowbotham et al. has described an incidence at 0.44% for hep-
tic metastases for malignancies with very few cases reported in the
iterature. [2] Hepatic failure following hepatic metastases though
are has been reported more for non-Hodgkins lymphoma unlike
etastatic breast cancer. [3] An aetiological association between
ertility drugs and breast cancer has not been reported to exist.
owever increase in oestrogen levels is associated with use of
lomiphene, a selective estrogen receptor modulator. We  rational-
ze that this may  promote the growth of a preexisting breast cancer.
e report the case of a 41 year old para 1Nigerian woman, who  had
een managed for secondary infertility with clomiphene, that pre-
ented with a T2 tumour of 3 months duration which emerged as
epatic metastases with liver failure. Her demise occured barely a
eek from presentation (Figs. 1 and 2).
The rapidity of progression of this disease with subsequentemise within a week of presentation is remarkable. We  believe
hat the prior use of clomiphene may  have escalated the progres-
ion of this T2 tumour. Though it has been reported widely that
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clomiphene raises levels of oestrogen to supraphysiological levels
[4] we  are not aware of a report associating the prior use of this
selective estrogen receptor modulator with the rapid progression
of a previously existing breast cancer. Again previous reports of
liver failure from hepatic metastases have occurred in subjects who
have been managed for breast cancer in the past. In addition, our
case deserves mention being a fresh diagnosis following a 3 month
history of a T2 breast tumour.
2. Presentation of case
A 41 year old para 1 lady was referred from a fertility clinic
with a 3 months history of a left breast lump and nipple bleeding.
She had been managed for secondary infertility with an extended
use of clomiphene having visited other fertility clinics. She had
no previous history of liver disease. Initial general examination
ﬁndings were unremarkable. Breast examination showed bloody
nipple discharge and a hard left breast lump measuring 4 by 3 cm
with no attachment to skin or underlying tissue. There was a single
discrete left axillary lymph node. Abdominal examination showed
an enlarged liver 6 cm from costal margin. Breast biopsy revealed
an invasive ductal carcinoma, positive progesterone receptor and
doubly overexpressed human epidermal growth factor receptors.
Abdominal ultrasound scan showed diffuse metastatic liver nod-
ules. Abdominal CT or MRI  was not immediately available. She
was staged T2N1M1. In the course of investigation, she developed
fever, increasing scleral icterus, malaise, drowsiness and right
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Fig. 1. Photomicrograph showing invasive ductal carcinoma.
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mFig. 2. Abdominal ultrasound photo showing a nodular liver.
ypochondrial pain. Liver function tests showed progressively
levating serum bilirubin and elevating aminotransferases. Viral
epatitis and HIV screening were negative. She was assessed
s having decompensating liver function from diffuse hepatic
etastases. She received taxane chemotherapy while anticipatingPEN  ACCESS
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herceptin administration. She continued to deteriorate with
deepening scleral icterus, drowsiness and confusion dying within
9 days following presentation.
3. Discussion
Our case was  being managed for infertility at other fertility
clinics before presenting with a 3 months history of a breast
lump/nipple bleeding and diagnosed with a T2 tumour with dif-
fuse liver metastases. This is considered a short duration for such
metastases and a rational explanation would be the presence of a
growth promoter, a history of clomiphene use which would result
in exponential increases in oestrogen levels, the breast cancer being
a hormone positive tumour.
Acute liver failure with liver metastases is rare being seen with
diffuse parenchymal inﬁltration as in our case. [5] Very few cases
have been reported in the literature with the prognosis more or less
dismal. The fertility treatments before presentation may  explain
the aggression of this disease within the short duration of three
months. Although several reports have not determined an aetio-
logical association between fertility drugs and breast cancer, other
reports do not deny a growth promotion in a preexisting breast
cancer being hormone dependent especially in our case which was
hormone positive. Again the tumour in our case was overexpressing
for the Her 2neu protein another factor in its aggression and rapid-
ity of spread. Our case tested negative for hepatitis B, a common
case of hepatic failure in our environment. Our  case did not respond
to hormonal manipulation with tamoxifen and continued to dete-
riorate. This further reiterates the need for breast cancer screening
before women  are placed on fertility drugs. A much needed call in
this era of an upsurge in fertility treatments.
Patients who had been adequately treated for breast cancer in
the past have been the subject of most reports with invasive ductal
carcinoma being the histological type as in our case. [5] However
our case was exceptional being a diagnosis at ﬁrst presentation
thus had not received any treatment nor had a history of liver
disease. Prodromal symptoms of fever, malaise, right upper quad-
rant pain have been reported to precede the onset of liver failure
as occurred in our case prior to commencing any treatment. [2].
Even though our case had chemotherapy to attempt to curtail the
metastases, the patient’s presentation with signs of deteriorating
liver function; elevating liver enzymes, increasing bilirubin levels,
right hypochondrial pain, drowsiness predated the administration
of chemotherapy. Although we  were unable to obtain an abdominal
CT to determine the extent of liver involvement of the liver metas-
tases, the abdominal ultrasound scan ﬁndings showed extensive
hepatic involvement.
Nieto et al. reported the peculiar case of fatal acute liver fail-
ure from a previously 4 year old indolent breast neoplasm in a
patient with a previously known liver disease [6]. The patients liver
metastases was reported to be widely inﬁltrating as in our case
with diffuse metastatic liver nodules. The occurrence of diffusely
inﬁltrating liver nodules has been reported to be most commonly
associated with acute liver failure [5]. Anorexia, jaundice, and dif-
ferent levels of altered mental status have all been described as
features in these cases of diffuse liver parenchymal involvement
from an aggressive breast cancer as occurred in our case [1]. Martelli
et al. have reported a metastatic breast cancer with rapidly progres-
sive liver failure but radiographically occult liver lesions; massive
hepatic inﬁltration being demonstrated at autopsy [7]. Another
worker described hepatic failure occurring from an occult breast
carcinoma [8]. Our case had hepatomegaly with demonstrable
diffuse liver nodules on abdominal ultrasound scan. Biochemical
elevations in the levels of aminotransferases, lactate dehydroge-
nase and alkaline phosphatases were prominent features in our
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ase as has been reported [5]. However coagulopathy, dissem-
nated intravascular coagulopathy and thrombocytopaenia were
ot observed in our case as has been described by other reports
5].
A rapid and aggressive course of the disease is described for
his disease with a very poor prognosis. The reported cases were
escribed as uniformly succumbing to the condition in a short time.
ome workers have suggested that up to 80–90% involvement of
epatic parenchyma by the tumour with hepatic failure likely pro-
ides explanation for the early demise of these reported cases [9], as
n our case. We  believe that the elevation of oestrogen levels from
ertility drugs over a period of time may  have promoted the growth
f this tumour and its consequent liver metastases with widespread
iver nodules within an observed 3 months clinical history. With the
ncrease in utilisation of fertility drugs, there comes a need for pre-
reatment screening and increased surveillance for breast cancer in
atients managed with fertility drugs.
. Conclusion
Breast cancer screening for patients before infertility treatments
nd continual surveillance while on such treatment is highly rec-
mmended. The poor prognosis of metastatic breast cancer with
cute hepatic failure with no effective treatments in published lit-
rature marks it as requiring more studies in a bid to upturn its
ismal outlook.
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